Genetics in Suicide Treatments, Modern Diagnosis Establishments

Lu DY*, Lu TR¹, Che JY¹, Yarla NS² and Wu HY¹

¹Shanghai University, Shanghai 200444, PR China
²Glam University, AP, India

Abstract
Antidepressants can relieve human depression and reduce human depressive symptoms—including human suicide prevention. Although the mechanisms of action for these drugs remained to be established, researches focusing on revealing the relationship between efficacy and toxicities of antidepressants have been initiated in China and US. To deal with this suicide prevention and side-effective, new initiatives and revolutionary ideas have been proposed and assessed. Hopefully, therapeutic efficacies and outcomes by antidepressant treatments can be improved for clinical trials in future.

Keywords: Human genome; Human suicide; Drug response; Mental disorder; Genetic diagnostics; Medicinal chemistry; Next generation sequencing

Introduction

Human suicide is a common symptom of depression/mental illness worldwide [1-7]. Owing to long term economic depression in recent years, human suicide might still persist among most countries. In order to reduce human suicide, some good examples and paradigms have been speculated and systematical investigations have been underway [1-7].

Past Achievements of Suicide Therapy

PG technology detecting genes of many biological or pharmacological interests is mainly divided into two general categories—predicting risks and response of drugs and drug absorption, distribution, metabolism and excretion (ADME) by polymorphisms of human drug metabolizing enzymes or abnormal neural molecular targets. Approximately 300 human metabolic enzymes have been found. The genetic polymorphism changes of metabolizing enzymes decrease or increase the blood concentrations of antidepressants by different rates of drug ADME, which decide main parts of drug toxicities in human bodies. The side effects (risks) predictions of different types of antidepressants in determine polymorphisms of ADME are relatively less dramatic and severe, such as fatigue and vomiting etc. [4-7]. Drug-toxic molecules and drug-targeted molecules are proposed to be different mechanisms of action in many ways. Neural molecules or receptors have been proposed to be major gene encoding for both the suicidal ideations occurrence (risk) and therapeutic responses/ outcomes [1-7]. How to systematically study the mechanisms of action that genes or biological molecules involve in suicide occurrence and therapies has been proposed early before. Favorable outcomes have been reported in this respect [8].

The best gene candidates for suicide therapy are not very clear now. Genetic panels affecting both drug-active and drug-toxic genes (molecules) in the same times might be optimal avenues for in-depth scientific investigations [9-16]. Other current achievements relating antidepressant drug therapies are offered in Table 1.

Medicinal Chemistry

Antidepressant agents belong to different categories of biological, genetic or molecular mechanisms or chemical molecules. Presently specifically genetic or molecular study for each antidepressant agent, such as citalopram etc. is the first step [17-21]. In future, finding the relationship between chemical structures of antidepressant agents and their impacts on different individuals may prove to be more potential and clinical significance. Similarly, it needs more money in conventional routes [17-18]. Can we brainstorm more efficient assessment systems? May we invent or apply some new patents that focus on this matter and be potential future trends? [4].

Technical Details

Like many biomedical factors aforementioned, laboratory facility supports and technical details also determine the quality of experimental and clinical study outcomes and are important avenues for further updating clinical therapeutic protocols and medication efficacy [22-24]. Previously, the severity of drug risks and drug responses are decided by different toxicity symptoms. Integration of these two different symptom score systems as a whole is the first step testifying previous arguments and triggering genetic investigations determining and predictions of drug risks and responses in one PG system and other interesting topics [22-27].

Collecting data of relationship between chemical, genetics, environmental factors and therapeutic efficacy/outcomes is unavoidable study for in-depth understanding many important problems relating to previous speculations. Moreover, worldwide cooperation for accumulating rare inheritable disease-cases and sufficient GWAS

Animal models and studies | Optogenetics GEM
---|---
Clinical PG studies | Human metabolic enzymes, such as CYP2D6 Drug-active or drug-toxic genes (SNPs)
Genome-wide association studies (GWAS) | More than 10 genetic alleles are discovered
Other biological systems | Molecular Bioinformatics

Table 1: Brief outlines of current achievements relating to antidepressant therapies.

*Corresponding author: Dr. Lu DY, School of Life Sciences, Shanghai University, Shanghai 200444, PR China. Tel: +862166163545; E-mail: ludyong@shu.edu.cn

Received September 18, 2017; Accepted September 25, 2017; Published October 04, 2017

Citation: Lu DY, Lu TR, Che JY, Yarla NS, Wu HY (2017) Genetics in Suicide Treatments, Modern Diagnosis Establishments. J Ment Disord Treat 3: 145. doi:10.4172/2471-271X.1000145

Copyright: © 2017 Lu DY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
(genome wide association study) data [9-16] is avenue to expedient the
study of many important issues of drug neural toxicity and therapies.

Genome-Wide Associate Study (GWAS)

Invitation of genome-wide association study (GWAS) of suicide
and antidepressant therapy PG might lead to the final solutions for
predicting neural toxicity (risks) and responses of antidepressants
to normal human beings. By taking GWAS, more than ten genetic allele
difference between normal and antidepressant susceptible humans
have been found. But only half of these alleles are statistical significance now.
It may be explained as being affected by other genetic or environmental
factors or shortages of human genomic sample sizes [22-25]. Next
generation sequencing (NGS) techniques will increase the speed of
genome sequencing (15,000-50,000 times) and dramatically reduce
the cost of genome sequencing (less than seven thousand US dollar
for one genome) [4-7]. In future, genome sequencing working forces
and researchers may be changed from biomedical major students into
mathematical or physics major students or scholars. The contributions
by mathematics and physics students or scholars for genomic
sequencing will be more significant than biomedical majored students
because of the increasing importance of large scale data manipulations
or analysis in NGS protocols. Moreover, after large scale PG study,
antidepressant treatments will be sophisticated and more effective
for each patient in future.

Other Technology

On the other hands, some basic biological, pharmacological and
toxicological information changes after antidepressant treatments,
such as optogenetic studies [25,26] or genetic engineering mice (GEM)
[27] and other new technologies and patents must also be used to assess
many opening hypotheses and systematic scientific studies, including
this one and finally update antidepressant therapy PG and other clinical
diagnostic and therapeutic systems. The techniques of optogenetic and
genetic engineering mice (GEM) are new endeavors that can be used to
study the functions and dysfunctions of specific genes in living bodies.
Nonetheless, they are newly discovered technology and large flood of
these approach and antidepressant therapy study will be soon done.
Only then, many longstanding controversies can be resolved. So in
future, a lot of intrinsic related things behind these differences can be
discovered and better achieved by increasing worldwide cooperative
efforts and activities in this regards. These researches will make great
difference and impacts on antidepressant therapies in future. They
are not only on medicinal chemistry, but also on pharmacology and
toxicology topics.

Clinical Treatments

There is no therapeutic ideology for suicide origination now.
Several types of diseases, such as mental disorders are possible targets
for drug intervention [16,28-30].

Conclusion

In future, modern diagnostics for suicide and treatments in clinics
might be strengthened. Increasing mandatory genetic/molecular/
image diagnostic trials might be required in most advanced countries
in future. Or even become a worldwide indispensable.

References

1. Lu DY (2017) Suicide Risks and Treatments New Ideas and Future
Perspectives. Lu DY (ed.) Nova Science Publishers.

2. Lu DY, Lu TR, Lu Y, Cao S (2017) Introduction for suicide study. Journal
Metabolic Syndrome 6: 227.

3. Lu DY, Wu HY, Cao S, Lu Y, Yarla NS, et al. (2017) Historical analysis of
suicide/mental disorder and current diagnostics in clinics. Suicide Risks and
Treatments, New Ideas and Future Perspectives. Nova Science Publishers.

4. Lu DY, Lu TR, Che JY, Zhu PP (2014) Genetics and bioinformatics studies of
antidepressant drug therapeutic efficacies and toxicities, a current overview.
CNS Drug Discov 9: 193-199.

5. Lu DY, Lu TR, Zhu PP, Che JY (2015) Genetics and bioinformatics study of
antidepressant drugs, recent advancements and future trends. Suicidal
Ideation: Predictors, Prevalence and Prevention. Weaver B (eds.).
Nova Science Publishing.

6. Lu DY, Lu TR, Zhu PP, Yarla NS, Wu HY (2017) Current suicide prediction,
metabolism and adverse reactions. Pharmacogenomics 14: 1191-1201.

7. Serafini G, Salano P, Amore M (2015) Suicidal ideation: A comprehensive
overview. Suicide Ideation: Predictors, Prevalence and Prevention. Weaver B
(ed.) Nova Science Publishing.

8. While D, Bickley H, Roscoe A, Windfuhr K, Rahaman S (2006) Implementation
of mental health service recommendations in England and Wales and suicide
rates, a cross-sectional and before-and-after observational study. Lancet 367:
1095-1012.

9. Menke A, Samann P, Kroiber S, Czamara D, Lucase S (2012) Polymorphisms
within the metabotropic glutamate receptor 1 gene are associated with
depression phenotypes. Psychoneuroendocrinology 37: 565-575

10. Brent D, Melhem N, Turecki G (2010) Pharmacogenomics of suicidal events.
Pharmacogenomics 11: 793-807.

11. Kim DK, Kim JW, Kim SW, Bernard J (2014) Method for providing information
on antidepressant therapeutic effect using single nucleotide polymorphism.

12. Laje G, Allen AS, Akula N, Manji H, Rush AJ, et al. (2009) Genome-wide
association study of suicidal ideation emerging during citalopram treatment
of depressed outpatients. Pharmacogenet Genomicians 19: 666-674.

13. Garriott HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, et al. (2010) A genome
wide association study of citalopram response in major depressive
disorder. Biol Psychiatry 67: 133-138.

14. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, et al. (2010) Genome-
wide pharmacogenetics of antidepressant response in the GENDEP project.
Am J Psychiatry 167: 555-564.

15. Menke A, Domschke K, Czamara D, Klenget T, Hennings J, et al. (2012) Genome-
wide association study of antidepressant treatment-emergent suicidal
ideation. Neuropsychopharmacology 37: 797-807.

16. Lu DY, Zhu PP, Wu HY, Yarla NS, Zhu H (2016) Human suicide study, is there
an associations between suicide and mental illness. Metabolomics 6: 186.

17. Lu DY, Lu TR, Ding J (2007) May genetic factors play a role in the risk of
antidepressant-induced suicide. Med Hypotheses 69: 1390-1381.

18. Lu DY, Lu TR, Zhu PP (2010) Undesired neural side-effects of a drug, a
chemical and genetic interrelated problem. Central Nervous System Agent
Medicinal Chemistry 10: 108-112.

19. Mc Allister-Williams R, Ferrier IN (2009) Pharmacological management of
unipolar affective disorder. Psychiatry 8: 113-119.

20. McAllister-Williams R, Ferrier IN (2009) Pharmacological management of
bipolar affective disorder. Psychiatry 8: 120-124.

21. Lu DY, Lu TR, Ding J, Wu HY, Yarla NS, et al. (2017) Therapeutic drug
developments and clinical utilities. Suicide Risks and Treatments, New Ideas and
Future Perspectives. Lu DY (ed.) Nova Science Publishers.

22. Lu DY, Lu TR, Zhu PP (2012) How can we pinpoint genetic involvement in
antidepressant-induced suicide? Adv Pharmacopoeidemio Drug Safety 1: 101.

23. Lu DY, Lu TR, Zhu PP (2013) Pharmacogenetics in neural toxicities of drugs.
Pharmacogenomics 14 : 1129-1131.

24. Lu DY, Lu TR, Zhu PP, Che JY (2016) The efficacies and toxicities of
antidepressant drugs in clinics, building the relationship between Chemo-
Genetics and Socio-Environments. Cent. Nerv. Syst. Agents Med. Chem 16: 12-18.

25. Kuo HW, Liu C, Teou HH, Liu SW, Lin M, et al. (2013) CYP1A2 genetic
polymorphisms are associated with early antidepressant escitalopram
metabolism and adverse reactions. Pharmacogenomics 14: 1191-1201.
26. Zhao Y, Xiong N, Liu Y, Zhou YH, Li NM, et al. (2013) Human dopamine transporter gene: differential regulation of 18-kb haplotypes. Pharmacogenomics 14: 1481-1494.

27. Youngstrom IA, Strowbridge BW (2012) Visual landmarks facilitate rodent, spatial navigation in virtual reality environment. Learn Mem 9: 84-90.

28. Kapur N, Gask L (2009) Introduction to suicide and self-harm. Psychiatry 8: 233-236.

29. Lu DY, Lu TR, Zhu PP, Cao S (2017) Different ranges of outside factors upon human suicidal rates and mortalities. Suicide Risks and Treatments, New Ideas and Future Perspectives. Lu DY (ed.) Nova Science Publishers.

30. Cornelius JR, Walker JD, Klima G, Fisher B (2015) Suicidal symptoms among veterans with chronic PTSD evaluated for treatment at a VA hospital. Suicidal Ideation: Predictors, Prevalence and Prevention. Weaver B (ed.) Nova Science Publishing.